Figure 3.

Three primary metabolites of esomeprazole were analyzed as indicators of cytochrome P450 2C19 (5′-OH-esomeprazole and 5-O-desmethyl esomeprazole) and cytochrome P450 3A4 (esomeprazole sulfone) activity. Data are normalized for differences in bioavailability by the ratios of the respective metabolites over the parent drug. Blue boxes show the subarachnoid hemorrhage (SAH) group and green the control group. Medians are the horizontal lines in the boxes that show the 25th and 75th quartiles. Outliers are shown by open circles and far outliers by asterisks. There were no significant differences between the groups and study days concerning CYP2C19 activity. However, the esomeprazole sulfone formation was substantially lower in the SAH cohort indicating very low CYP3A enzyme activity.